A Mouse Model to Assess STAT3 and STAT5A/B Combined Inhibition in Health and Disease Conditions

Genetically-engineered mouse models (GEMMs) lacking diseased-associated gene(s) globally or in a tissue-specific manner represent an attractive tool with which to assess the efficacy and toxicity of targeted pharmacological inhibitors. and transcription factors have been implicated in several pathop...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 11; no. 9; p. 1226
Main Authors Moll, Herwig P, Mohrherr, Julian, Blaas, Leander, Musteanu, Monica, Stiedl, Patricia, Grabner, Beatrice, Zboray, Katalin, König, Margit, Stoiber, Dagmar, Rülicke, Thomas, Strehl, Sabine, Eferl, Robert, Casanova, Emilio
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 22.08.2019
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Genetically-engineered mouse models (GEMMs) lacking diseased-associated gene(s) globally or in a tissue-specific manner represent an attractive tool with which to assess the efficacy and toxicity of targeted pharmacological inhibitors. and transcription factors have been implicated in several pathophysiological conditions, and pharmacological inhibition of both transcription factors has been proposed to treat certain diseases, such as malignancies. To model combined inhibition of and we have developed a GEMM harboring a flox - allele ( mice) and generated mice lacking and in hepatocytes ( ). mice exhibited a marked reduction of STAT3, STAT5A and STAT5B proteins in the liver and developed steatosis, a phenotype that resembles mice lacking in hepatocytes. In addition, embryonic deletion of and ( mice) resulted in lethality, similar to mice. This data illustrates that mice are functional and can be used as a valuable tool to model the combined inhibition of and in tumorigenesis and other diseases.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers11091226